U.S. Markets closed

Will This Downbeat Biotech Regain Investor Trust With ALS Drugs?

ALLISON GATLIN
Will This Downbeat Biotech Regain Investor Trust With ALS Drugs?

Biogen stock dipped Thursday after the biotech company unveiled plans for its ALS treatments. Analysts were largely unimpressed, and don't expect the drugs to bring in much in sales.